Biohaven’s previously rejected rare disease drug to get fresh FDA review

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 22 Oct, 16:24 UTC

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease medicine spurned by previous FDA leadership.

policyscience

Sources

• T2Biohaven’s previously rejected rare disease drug to get fresh FDA reviewBioPharma Dive / Healthcare Dive / MedTech Dive22 Oct, 16:24